Molecular Diagnostics of Parkinson’s Disease

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 347

Special Issue Editors


E-Mail Website
Guest Editor
Department of Neurology, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Interests: molecular mechanisms of neurodegeneration; animal models of neurodegenerative diseases; neuroimmunological and neuroinflammatory aspects of neurodegenerative diseases; preclinical evaluation of novel therapeutics for neurodegenerative diseases; biomarker discovery for CNS diseases

E-Mail
Guest Editor
Department of Neurology, Institute of Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
Interests: neurodegenerative disease and neuroprotection; drug discovery; pharmacology and neurotoxicology; gut-brain axis; mitochondrial dysfunction; animal models pharmacogenomics and HPLC Methods in neurodegenerative diseases.

Special Issue Information

Parkinson’s disease (PD) is the second most common neurodegenerative disorder, characterized by the preferential loss of dopamine (DA) neurons in the substantia nigra pars compacta (SNPc) region of the midbrain, leading to movement dysfunction. Aging is a primary risk factor for PD, but genetic and environmental factors also play vital roles. Although 90% of PD is sporadic in general, many familial PD-linked genes cause autosomal dominant or recessive forms of the disease. The cardinal features of PD are bradykinesia, resting tremor, rigidity, and postural instability. There is no cure or prevention for PD, while the current treatment options only provide symptomatic relief. The key pathological hallmarks of PD are Lewy bodies (LBs) and Lewy neurites (LNs), characterized by the accumulation of proteinaceous cytoplasmic and neuritic inclusions containing α-synuclein as a major constituent.

Although there is accumulating evidence suggesting that the abnormal accumulation of misfolded α-synuclein triggers selective loss of DA neurons in PD, the underlying molecular mechanisms of neurodegeneration are still poorly understood. Although SNPc and striatum in the central nervous system (CNS) are primarily affected in PD, the accumulation of pathological α-synuclein in other CNS regions may contribute to many non-motor symptoms, such as cognitive impairment, autonomic dysfunctions, neuropsychiatric, and sleep disorders and others. On the other hand, as there is no biomarker for PD, we have an urgent need to discover PD biomarkers which could potentially facilitate diagnosis and treatments.

In this Special Issue, we welcome research studies and/or reviews on the highlighted topics. Studies identifying molecular pathways of neurodegeneration with translational implications and preclinical studies using advanced and/or novel animal models are especially welcome. We are also interested in studies on biomarker discovery. In particular, studies identifying potential prognostic, diagnostic, progression or target engagement biomarkers, and/or biomarkers distinguishing PD from other related synucleinopathies and dementia will receive special consideration.

Dr. Saurav Brahmachari
Dr. Senthilkumar S. Karuppagounder
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Parkinson’s disease
  • α-synuclein
  • Biomarkers
  • Dopamine
  • Animal models

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers

There is no accepted submissions to this special issue at this moment.
Back to TopTop